Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Online First

A paradigm shift in the management of relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma (NHL) has evolved in recent years. With increased use of targeted therapies, ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, is an integral therapeutic option for patients with treatment-naïve and treatment-experienced CLL or low-grade NHL. Ibrutinib therapy demonstrated superior overall response rates compared with ofatumumab and other agents in treatment-experienced patients with CLL.
Prostate cancer is the second leading cause of cancer-related mortality, and accounts for 10% of cancer-related deaths in American men. It is estimated that 1 in 9 men will have prostate cancer during their lifetime, and an estimated 161,363 new cases and 26,730 prostate cancer–related deaths are expected in the United States in 2017.
Pharmacists are becoming increasingly involved in cancer care. This raises a vital question: How aware are pharmacy students of the expanding roles and opportunities in oncology pharmacy?
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer‑predisposing gene. Although this association has been noted for a while, until recently there was not enough data available to determine the lifetime ovarian cancer risk for women with a mutation in some of these genes.
Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner.
What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
Two pilot programs aimed at reducing the utilization of in­appropriate testosterone replacement therapy, particularly in the treatment of men with age-related hypogonadism, have shown success in raising awareness of evidence and safety concerns.
The Cancer Clinical Trials Office (CCTO) at Stanford University, Palo Alto, CA, oversees a large clinical trials program. It provides regulatory, financial, research, and educational services for investigators conducting clinical trials.
Page 1 of 2
Results 1 - 10 of 11